A detailed history of Hrt Financial LP transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Hrt Financial LP holds 55,369 shares of TCRX stock, worth $108,523. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,369
Holding current value
$108,523
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$1.1 - $1.8 $60,905 - $99,664
55,369 New
55,369 $80,000
Q1 2024

May 13, 2024

BUY
$4.89 - $8.3 $170,118 - $288,748
34,789 New
34,789 $276,000
Q1 2022

May 16, 2022

SELL
$2.8 - $5.4 $58,321 - $112,476
-20,829 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.5 - $9.05 $93,730 - $188,502
20,829 New
20,829 $93,000

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $37.1M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.